Navigation Links
Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call
Date:3/5/2009

SEATTLE, March 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the fourth quarter and year ended Dec. 31, 2008, after the close of market on March 12, 2009. The company's earnings conference call will take place March 12, 2009, at 2 p.m. Pacific Time, 5 p.m. Eastern Time.

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com.

Fourth-Quarter and Year-Ended 2008 Earnings Conference Call: 2 p.m. PDT/5 p.m. EDT, March 12, 2009

Trubion will host a conference call and webcast to discuss its fourth-quarter and year-ended 2008 financial results and provide an update on business activities. The call will be held March 12 at 2 p.m. Pacific Time, 5 p.m. Eastern Time. The live event will be available from Trubion's website at http://investors.trubion.com, or by calling (719) 325-4831 or (877) 852-6579. A replay of the discussion will be available beginning 8 p.m. Eastern Time from Trubion's website or by calling (719) 457-0820 or (888) 203-1112 and entering 5983743. The telephone replay will be available until March 19, 2009.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom dru
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
2. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
3. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
4. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Karmanos Cancer Institute Announces Interim Leadership
7. Sysmex Corporation Announces Organizational Changes
8. IDRI Announces Appointment of Dr. Karen Auditore-Hargreaves as SVP, Scientific Affairs
9. Kensey Nash Announces Appointment of Chief Financial Officer
10. HMS Holdings Corp. Announces Executive Promotions
11. Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...as too short to draw definite conclusions, experts... News) -- In diabetic patients with blocked corona...outcomes at one year whether patients undergo bypa...esearchers report. , Bypass surgery has been th...ronary artery disease. However, less invasive appr...
(Date:11/25/2009)...ees few signs of trouble with the H1N1 vaccine, ,...- The ongoing H1N1 swine flu pandemic may be drivi...unger patients, a U.S. health official said Wednes...eumococcal infections around the country," Dr. Ann...munization and Respiratory Diseases at the U.S. Ce...
(Date:11/25/2009)...ectal cancer also can reverse a rare stomach disor...r the disease, researchers at Vanderbilt Universit...sease causes thickening of the stomach lining, sev...s anemia and swelling in the feet and ankles due t... gastric cancer. Previously, the only effective tr...
(Date:11/25/2009)...itiative expands to include cost-effective, sustai...d healthcare professionals in developing world. ,...vember 25, 2009 -- Elluminate, Inc. , the leader ...ons that support 21st century teaching, learning,... and Ice initiative was awarded iNACOL,s first-e...
(Date:11/25/2009)...PRNewswire/--dazzlesmile,llc www.dazzlesmile.com a...e.com havefileda67-pagefederallawsuitagainstEpicAd...lms,FarendServicesLimited,andAtLastFulfillment.The...CourtfortheDistrictofUtah,allegesmassivenationalco...teethwhiteningproducts,violationsoftheRacketeering...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2
...y as it is better than sequential planning of with...ing can be easily quit// if a decision is taking i...e fruitful sometime. But the researchers at Un...ed suddenly succeeded for at least six months, com...
...s now medical colleges all set to shock parents of...ctors//. This goes for people based in Karnatak...remely high for 2006-07 session. The respite co.... The college which quoted the highest annual fee...
...Bio beer which contains various herbs and vitamins...takers, as the new beer does not increase obesity ... The beer, invented by Srinivasa Amarnath over 10...and hops. The vitamin-rich beer is five perc...
...t Therapy Unit of the University of Navarra's Ana ...nducting basic research by the Danone Institute. T...n a program// aimed at defining individualized tre...hormonal and metabolic response of women who are o...
...regard to a massive study concerning the bird flu ...t the St. Jude Children's Research Hospital. This ...egarding the proteins// and genes of these viruse... effects on the human race. The Infectious Disease...
...iversity of Pittsburgh said that they have genetic...contains the components of the deadly strain H5N1....ete protection to mice and chickens from infection...d in cells and very easily produced in large amoun...
Other Medicine News:Health News:Vaccine to protect birds against avian flu, engineered 2
(Date:11/25/2009)...RK,Nov.25/PRNewswire/--Reportlinker.comannouncesth...e: ,, IntranasalDrugDelivery-USMarketTrends&am...ntranasal-Drug-Delivery---US-Market-Trends--Analys...witnessinganexpansionoftherapeuticapplicationsfrom...edeliveryofsystemictherapeuticdrugs.Thefutureofthe...
(Date:11/25/2009)...AINVIEW,Calif.,Nov.25/PRNewswire/-- ChemoCentryx,...theCompany,sPROTECT-1(theProspectiveRandomizedOral...EN(TM)(CCX282-B)inpatientswithmoderate-to-severeCr...ablesafetyandtolerabilityprofile.Thestudydemonstra...seseverityasdefinedasa70-pointdecreaseintheCrohn,s...
(Date:11/24/2009)...E,Calif.,Nov.24/PRNewswire-FirstCall/--Endologix,I...atmentsforaorticdisorders,announcedtodaythatithasf...epatentinfringementlawsuitbroughtagainstitinOctobe...DistrictCourtinIndianapolis,Indiana. ,, Endolog...tedStatesPatentandTrademarkOffice(USPTO)conductspr...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 1Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 2Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 3Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 4Reportlinker Adds Novo Nordisk A S 3A PharmaVitae Profile 58967 5Autism Stats Exaggerated 3A Parents Pushing Back This Weekend 58962 1Autism Stats Exaggerated 3A Parents Pushing Back This Weekend 58962 2Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports 58957 1Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports 58957 2Integrated Benefits Institute Announces Availability of 2008 IBI Benchmarking Industry Reports 58957 3
...utics,Inc. (CTI) (Nasdaq: CTIC ; MTA) today annou... accepted for review CTI,s Marketing Authorization...glumex, CT-2103) for,first-line treatment of patie...COG (Eastern Cooperative Oncology Group) performan...ginning of March. The validation of the MAA,for XY...
...ics, Inc.,(Nasdaq: CVTX ) today announced new dat... of the American College of Cardiology shows that,...gnificantly reduced the,risk of recurrent ischemia...fication of antianginal therapy (p=0.009) in angin..., Additionally, Ranexa significantly improved all...
Other Medicine Technology:European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 2European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 3European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 4CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 2CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 3
Mosaic
...a Windows 2000 PC based EEG with high performance ...are. EEG-9200 provides high quality performance fr...ep lab or EEG lab. Quality EEG recording is assure...ax has high performance, high sensitivity amplifie...
Neuropack MEB-9100 Series
X-SIZER Catheter System
Medicine Products: